Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.52 USD | -1.68% | -2.24% | +91.69% |
05-02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |